The mutational landscape of primary and metastatic prostate cancers have been robustly assessed through whole exome sequencing (WES) of tumors. These studies have identified multiple recurrently mutated genes that typically alter the functions of established cancer pathways, including androgen signaling, DNA repair, Wnt signaling, and PI3K signaling. Other pathways, such as splicing or SWI/SNF, have not been typically associated with prostate cancer from a somatic mutation perspective. This may be partially explained by the low mutational burden of prostate cancer. We hypothesized that mutation analysis of a uniformly analyzed large cohort of prostate cancer would reveal new significantly mutated genes and pathways.
